A Case against Heparin Therapy of Intravascular Coagulation^[*]

Summary

Administration of a potentially dangerous drug like heparin should not be based on theoretical considerations and innumerable case reports but 1) on a firm diagnosis and 2) on a critical evaluation of the clinical benefit.

The validity of criteria for the diagnosis of intravascular coagulation (IC) is discussed. It is emphasized in particular that loss of fibrinogen into extravascular spaces can only be excluded by assays of the level and disappearance rate of serum proteins not subject to the proteolytic action of thrombin or plasmin.

Even when the diagnosis can be reasonably established, heparin therapy in a particular condition should only be advocated if its clinical benefit has been demonstrated in controlled clinical trials.

Our conviction that heparin has as yet a small if any place in the management of patients with so-called intravascular coagulations is based mainly on two sets of arguments, one stemming from a critique of the diagnosis of IC, the other from a general attitude in the evaluation of therapeutic procedures.

^* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.

• References

• 1 Benz J. J. Clotting factors and fibrinogen split products in the extravascular space. Thrombosis et Diathesis Haemorrhagica 1968; 19: 226
• 2 Bleyl U, Kuhn W, Graeff H. Retikuloendotheliale Clearance intravasaler Fibrinmonomere in der Milz. Thrombosis et Diathesis Haemorrhagica 1969; 22: 87
• 3 Charm S. E, Wong B. L. Shear degradation of fibrinogen in the circulation. Science 1970; 170: 466
• 4 Clawson C, White J. G. Platelet interaction with bacteria. II. Fate of the bacteria. American Journal of Pathology 1971; 65: 381
• 5 Cohen P, Gardner F. H. Thrombocytopenia, a laboratory sign and complication of Gram-negative bacteremic infection. Archives of Internal Medicine 1966; 117: 113
• 6 Fletcher A. P, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. Journal of Clinical Investigation 1964; 43: 681
• 7 Gazzard B. G, Clark R, Borirakchanyavat V, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 1974; 15: 89
• 8 Gmür J, Ganzoni N, Straub P. W. Observations on blood coagulation, fibrinolysis and hemolysis in severe burns. XIIIth International Congress of Hematology, Munich, August 2-8 1970 Abstract vol. p. 107 1970;
• 9 Herold R, Meier W. E, Straub P. W. Surface accumulation and reduced survival of I¹²⁵-fibrinogen during wound healing. Helvetica medica Acta 1973; 37: 55
• 10 Herold R, Straub P. W. Acute hepatic necrosis of hepatitis and mushroom poisoning. The value of coagulation tests in their differentiation, prognostic assessment and pathogenesis. Helvetica medica Acta 1973; 37: 5
• 11 Hillenbrand P, Parbhoo S. P, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974; 15: 83
• 12 Kolodié L, Rachail M, Seigneurin D. Dosage des produits de dégradation de la fibrine (P.D.F.) dans le sérum au cours des cirrhoses du foie. Lyon Médical 1973; 229: 671
• 13 Lee L. Reticuloendothelial clearance of circulating fibrin in the pathogenesis of the generalized Shwartzman reaction. Journal of Experimental Medicine 1962; 115: 1065
• 14 Lewis J. H, Szeto Z. F. Clearance of infused fibrin. Federation Proceedings 1965; 24: 840
• 15 Lewis J. H, Szeto I. L. F, Curiel D. G. Leukofibrinolysis. Blood 1972; 40: 844
• 16 Post R. M, Desforges J. F. Thrombocytopenic effect of ethanol infusion. Blood 1968; 31: 344
• 17 Rake M. O, Flute P. T, Shilkin K. B, Lewis M. L, Winch J, Williams R. Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet II: 1215 1971;
• 18 Riedler G. F, Straub P. W, Frick P. G. Thrombocytopenia in septicemia. A clinical study for the evaluation of its incidence and diagnostic value. Helvetica medica Acta 1972; 36: 23
• 19 Sherman L. A, Fletcher A.P, Sherry S. In vivo transformation between fibrinogens of varying ethanol solubilities : A pathway of fibrinogen catabolism. Journal of Laboratory and Clinical Medicine 1969; 73: 574
• 20 Straub P. W, Frick P. G. The coagulation disorder in promyelocytic leukemia. Helvetica medica Acta 1967; 34: 44
• 21 Straub P. W. Chronic intravascular coagulation. Clinical spectrum and diagnostic criteria, with special emphasis on metabolism, distribution and localization of I¹³¹- fibrinogen. Acta medica Scandinavica Suppl. 526 1971;
• 22 Straub P. W. Chronic intravascular coagulation: Localized or generalized? With evidence for thrombus turnover. Thrombosis et Diathesis Haemorrhagica Suppl. 1973; 56: 1